Abstract: HR-positive HER2 low-expressing breast cancer is a new hotspot therapeutic subtype, accounting for approximately 53.7% of all breast cancers. These patients tend to have a higher rate of lymph node metastasis and may have poorer sensitivity to both neoadjuvant chemotherapy and conventional anti-HER2 therapy, and exploring therapeutic strategies for this subtype of patient is a current clinical challenge.Therapeutic strategies for HR-positive HER2 low-expressing breast cancers are constantly being updated, including CDK4/6 inhibitors across the lines of therapy, and next-generation ADC agents such as T-DXd. With the accumulation of more high-level evidence-based evidence for HR-positive HER2 low-expression breast cancer in the future, the research data will provide more practical support for the precise diagnosis and treatment, and further improve the prognosis of HR-positive HER2 low-expression breast cancer patients.